Skip to main content

Variability of Guidelines on the Perioperative Use of DMARDs in Rheumatic Diseases Patients

More effective treatments in patients with rheumatic diseases have resulted in less need for major surgery, yet a substantial number of RMD patients will undergo surgery often in the setting of DMARDs use. A scoping review looked at numerous clinical practice guidelines/recommendations for the perioperative management of DMARDs and found inconsistencies and low quality evidence, with great reliance on conditional (expert opinion) recommendations.
Manifestations and Treatment in Relapsing Polychondritis

A large multicenter cohort study of Relapsing Polychondritis (RP) describes the clinical manifestations and treatment approaches to this rare, heterogeneous, multisystem disease.

NHANES study (2007 to 2020) of 19,904 participants (≥ 20 years), including 1,477 RA pts. Prevalence of kidney stones

Social Author Name
Dr. John Cush
Tweet Content
NHANES study (2007 to 2020) of 19,904 participants (≥ 20 years), including 1,477 RA pts. Prevalence of kidney stones was higher in RA (17% vs. 8%, p < 0.001) (OR = 1.77) https://t.co/0NZKQdQWR8 https://t.co/BRZ1RTNh5W
Osteoporosis treatment benefits people older than 80

People who are older than 80 should be considered for osteoporosis treatment after a fracture to avoid further risk, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.

“The burden of osteoporosis is rising as the global population ages rapidly,” said Gianina Flocco, M.D., a resident at the Cleveland Clinic in Cleveland, Ohio. “Our study supports the initiation of osteoporosis treatment after a fracture in people older than 80 years, as it has been shown to decrease both hospitalization and mortality.”

Interstitial Lung Disease and Lung Cancer Risk

A large prospective cohort study found that interstitial lung disease (ILD) is associated with an increased risk of lung cancer.

This cohort study of 5,425,976 used a a sibling-controlled design to account for genetic factors. Data was taken from the Swedish Total Population Register and Swedish Multi-generation Register. Primary outcomes were multivariable hazard ratios (HRs) and 95% CIs.

From 5.4 million individuals (including 14 624 with ILD), during a 30-year follow-up period, lung cancer was seen: 

RA study shows rapid remission (DAS28-CRP < 2.6 <12 wks) occurred in 28% of 865 pts & assoc. w/ better res

Social Author Name
Dr. John Cush
Tweet Content
RA study shows rapid remission (DAS28-CRP < 2.6 <12 wks) occurred in 28% of 865 pts & assoc. w/ better respsonses at week 26. Also rapid remission had signif. 5 yr benefits (SJC, TJC, Fatigue, HAQ, pain, & most PRO outcomes. https://t.co/2tvxS8oXP2 https://t.co/YAFGAri3Uj

10-20% of IBD pts have IBD-assoc. spondyloarthritis, as either peripheral arthritis or axial Dz, subclinical gut inflamm

Social Author Name
Dr. John Cush
Tweet Content
10-20% of IBD pts have IBD-assoc. spondyloarthritis, as either peripheral arthritis or axial Dz, subclinical gut inflammation w/ IL-23–IL-17–TNFα playing central roles. TNFi & JAKi Rx is effective, but IL-17i may exacerbate IBD (vedolizumab??) Review here>> https://t.co/kNIAi55Y7z

HHS secretary Abruptly Cancels USPSTF Meeting on July 10 - to discuss diet, physical activity, and weight loss to preven

Social Author Name
Dr. John Cush
Tweet Content
HHS secretary Abruptly Cancels USPSTF Meeting on July 10 - to discuss diet, physical activity, and weight loss to prevent cardiovascular disease in adults. An HHS spokesperson did not give a reason. https://t.co/IqNOUWeVA4 https://t.co/0AmxQ1ZAcQ

CMS to Test Prior Authorization Model in Traditional Medicare The Centers for Medicare & Medicaid Services (CMS) a

Social Author Name
Dr. John Cush
Tweet Content
CMS to Test Prior Authorization Model in Traditional Medicare The Centers for Medicare & Medicaid Services (CMS) announced a new experimental model late last week to streamline some prior authorizations under the traditional Medicare program, but some politicians and experts https://t.co/o8iV9Bb6Ir

No Increased Malignancy Risk with Ixekizumab A pooled analysis of 25 randomized clinical trials affirms the safety of

Social Author Name
Dr. John Cush
Tweet Content
No Increased Malignancy Risk with Ixekizumab A pooled analysis of 25 randomized clinical trials affirms the safety of ixekizumab (IXE) when used to treat patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA). The observed incidences of https://t.co/7dAoQyeq5x
Subscribe to
×